December 2025

Deliver non-interventional studies, research collaborations, and investigator-initiated trials, managing spend and forecasts. Represent Study Management operations at Therapy Area Medical Affairs Team meetings.

Manage core HEVA communication processes, templates, and products across the portfolio in accordance to the scientific and value messages aligned with Core Value Dossier, the US AMCP dossier, and HEVA contributions as appropriate to other submissions

Sandoz the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg).

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.